A significant division has arisen in South Korea’s thriving botulinum toxin industry regarding the government’s restrictions on manufacturing technology. This dispute contrasts companies eager to accelerate international expansion with those cautioning that deregulation could jeopardize essential industrial knowledge.
Korean botulinum toxin exports have surged from $223 million in 2022 to a projected $500 million in 2025. The neurotoxin, commonly known through brand names like Botox, is primarily used in aesthetic procedures to diminish wrinkles and fine lines.
The core of the debate involves the government’s classification of botulinum toxin production technology as a national core technology (NCT) since 2010. This classification necessitates regulatory scrutiny for certain overseas technology transfers and foreign investment activities. In 2016, the designation was expanded to include toxin-producing strains.
The call for deregulation gained traction in 2023 when Daewoong Pharmaceutical advocated for the removal of the NCT designation. Recent findings presented at a National Assembly seminar on October 15 revealed that 14 out of 17 domestic botulinum toxin companies—approximately 82.4%—support lifting the technology from the protected list.
Proponents of deregulation argue that the current restrictions hinder global expansion, resulting in delays of licensing agreements, joint ventures, and technology transfers. Industry officials estimate that the time taken for government approvals, which can range from four to six months, leads to lost deals and a cost of 90 billion to 100 billion won ($67 million to $75 million) annually.
During the seminar, Choi Kyu-jin, an attorney at D&A law firm, emphasized that global competitiveness in the botulinum toxin market increasingly relies on manufacturing standards and brand recognition rather than access to bacterial strains or fundamental production technology. Similarly, Konkuk University professor Lee Seung-hyun noted that the technology has become widely commercialized internationally and suggested that it no longer requires the same level of government protection.
However, opponents of deregulation caution that lifting the NCT designation could weaken safeguards surrounding specialized manufacturing processes, which are often considered trade secrets. They argue that successful commercial production involves more than simply obtaining bacterial strains or applying methods found in scientific literature. Processes such as cultivating strains, extracting and purifying toxins, and maintaining product quality demand significant expertise that might not be patent-protected.
Concerns about counterfeit and unauthorized botulinum toxin products, particularly in the United States, have heightened these worries. Korean manufacturers have reported instances of counterfeit products bearing their brand names circulating through unofficial channels.
While the NCT designation does not directly address counterfeit medicines or illegal distribution, it offers a legal framework that helps prevent unauthorized overseas transfers of protected manufacturing technology. Violations of designated technology can result in government investigations and penalties under the Industrial Technology Protection Act.
The final decision regarding the NCT status of botulinum toxin production technology lies with the Ministry of Trade, Industry and Energy, which is currently reviewing 79 designated national core technologies, including those related to botulinum toxin. A completion date for the review has not yet been announced.
